Characterization of intramuscular Isoflupredone acetate in horses: pharmacokinetics and effects on anti-inflammatory mediators and plasma electrolytes.

Isoflupredone acetate (IPA) administered intramuscularly in horses shows prolonged presence in the body and significant effects on anti-inflammatory markers and electrolytes. This study describes the drug’s pharmacokinetics, impacts on inflammation mediators, and implications for withdrawal times in performance horses.

Study Objective and Design

• The study aimed to characterize the pharmacokinetics and pharmacodynamics of isoflupredone acetate (IPA) after intramuscular (IM) administration in horses.
• Twelve horses received a single 20 mg IM dose of IPA.
• Blood samples were collected starting at 5 minutes post-injection, with urine collected starting at 24 hours, extending up to 312-360 hours for measurement of drug concentration and effects.

Pharmacokinetics of Isoflupredone Acetate

• Concentration (Cmax) of isoflupredone reached a peak of approximately 1.55 ng/mL.
• Time to peak concentration (Tmax) had a median of 3.5 hours, ranging from 0.16 to 5.0 hours.
• The terminal half-life was long, averaging 39.6 ± 22.1 hours, indicating a slow elimination from the bloodstream.
• A one-compartment pharmacokinetic model best fit the data, simplifying the understanding of the drug’s distribution and elimination.
• Using Monte Carlo simulations with a 1000 horse population, the study recommends a withdrawal time of 10 days for IPA to fall below the regulatory screening limit of 100 pg/mL in 99% of horses.
• Urine samples showed isoflupredone levels below quantitation limit (0.05 ng/mL) by 360 hours post-injection.

Pharmacodynamic Effects on Inflammatory Biomarkers

• Endogenous cortisol, an indicator of steroid activity, was significantly suppressed for the entire 312-hour observation period.
• Ex vivo stimulation of blood with lipopolysaccharide and calcium ionophore, which induce inflammation, lead to increases in several cyclooxygenase and 15-lipoxygenase-derived inflammatory biomarkers, suggesting these pathways were not fully inhibited by the IPA concentrations achieved.
• However, concentrations of leukotriene B4 and 5-HETE, products of 5-lipoxygenase, were significantly decreased, indicating that this enzyme pathway was suppressed by isoflupredone.

Effects on Plasma Electrolytes and Renal Function

• A single IM dose of IPA caused hypokalemia (low blood potassium levels) in the treated horses.
• This was accompanied by an increased fractional excretion of potassium in the urine, suggesting enhanced renal potassium loss caused by the drug.

Conclusions and Implications for Use in Performance Horses

• The prolonged half-life and detection time of intramuscular IPA signify that a longer withdrawal period is required to avoid positive doping tests in competition horses.
• Though IPA exerts some anti-inflammatory effects by suppressing 5-lipoxygenase activity, the drug may not fully suppress all inflammatory pathways at the concentrations attained through IM administration.
• The hypokalemia observed after dosing highlights the need to monitor electrolytes, as corticosteroids can disrupt electrolyte balance, potentially affecting horse health and performance.

Overall Significance

• This study fills an important knowledge gap about the behavior and effects of intramuscularly administered isoflupredone acetate in horses.
• Findings assist veterinarians in optimizing dosing schedules, managing withdrawal times prior to competitions, and understanding side effects related to inflammation modulation and electrolyte disturbances.
• These insights improve the safe and responsible use of corticosteroids in equine medicine, enhancing therapeutic outcomes while minimizing doping risks.